IQVIA RDS Inc.
11
2
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
36%
4 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
Role: collaborator
Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis
Role: collaborator
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
Role: collaborator
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
Role: collaborator
Safety and Efficacy of J147 in Acute Ischemic Stroke
Role: collaborator
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease
Role: collaborator
Oral Administration of Actitan-F in Paediatric Diarrhoea
Role: collaborator
Growth and Safety Clinical Trial on a New Infant Formula
Role: collaborator
A Study Of IMM47 In Subjects With Advanced Solid Tumors
Role: collaborator
Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.
Role: collaborator
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Role: collaborator
All 11 trials loaded